Rees, M., Lasica, M., Kalff, A., Low, M., Harrup, R., Lai, H. C., Sidiqi, M. H., Doo, N. W., Routledge, D., Hocking, J., Campbell, P., Heenan, J., Horvath, N., Chien, N., Renwick, W., McCaughan, G., Eek, R., Lenton, D., Gazdar, S. G., Mazumdar, D., Butcher, B., Mollee, P., Quach, H. (2025). Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND). Blood. https://doi.org/10.1182/blood-2025-4039